Seeking Novel Immune-Inflammatory Targets, Pathways, and Therapies



Almirall, S.A. is looking to sponsor research collaborations investigating novel targets, pathways, or therapeutic candidates relating to chronic immune-inflammatory diseases. Academics and university departments are invited to submit relevant, non-confidential research proposals using the application form linked below. The team at Almirall are interested in sponsoring early-stage research programmes focused on target identification and validation, through to later stage applications progressing therapeutic opportunities into clinical settings.

Submissions will be assessed and, where appropriate, teams selected for funding of up to €250k per project in early November 2019.

Further information

Disease interest

Of highest priority are chronic immune-inflammatory skin diseases like atopic dermatitis, psoriasis, lichen planus, hidradenitis suppurativa, vitiligo or alopecia areata, as well as orphan diseases such as pemphigus vulgaris, epidermolysis bullosa or bulloid pemphigus.

However, projects in chronic immune-inflammatory diseases from other therapeutic areas (rheumatoid arthritis, multiple sclerosis, IBD, etc) would also be in scope provided the mechanisms/targets/pathways are common (they are not organ-specific).

Therapeutic opportunities

- Modalities of interest: Of highest priority are biologics, novel chemical entities, and gene therapy approaches, though other approaches will be considered
- Development stage: Basic research through to late pre-clinical development

Jurisdictions of interest

Worldwide

Funding and Submission information

Please find essential information regarding funding here

Please submit research proposals using the template found here by 30th September

Opportunities sought

Research projects

Submissions

Please submit relevant, non-confidential opportunities or questions to discover@in-part.co.uk

Using subject header: **Immune-Inflammatory Disease**

Before: **30th September 2019**

almirall

Almirall, S.A. is a pharmaceutical company committed to providing valuable medicines to patients worldwide. The company researches, develops, manufactures and markets proprietary medicines as well as licensed products, in areas with unmet medical needs. Today, their products are available in over 70 countries on five continents, through their 13 affiliates and a strategic partnership network.